Drugs / RCS-21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06752122 | Feb 2025 → Jun 2026 overdue | — | RNATICS GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-08 | RNATICS GmbH | Results Underlying science of RNATICS’ technology published in Nature Communications rnatics.com ↗
The paper describes the first-in-class mechanism to efficiently target RNA therapeutics to alveolar macrophages and its therapeutic potential. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | RNATICS GmbH | RNATICS received €2.7 million for the clinical development of RCS-21 rnatics.com ↗ |
| 2023-08-08 | RNATICS GmbH | Underlying science of RNATICS’ technology published in Nature Communications rnatics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RCS-21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752122 ↗ |
| Route | Inhaled | “Inhalation of a single dose.” NCT06752122 ↗ |